MX2021001145A - Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico. - Google Patents

Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.

Info

Publication number
MX2021001145A
MX2021001145A MX2021001145A MX2021001145A MX2021001145A MX 2021001145 A MX2021001145 A MX 2021001145A MX 2021001145 A MX2021001145 A MX 2021001145A MX 2021001145 A MX2021001145 A MX 2021001145A MX 2021001145 A MX2021001145 A MX 2021001145A
Authority
MX
Mexico
Prior art keywords
active pharmaceutical
pharmaceutical ingredients
immediate release
release formulation
treatment
Prior art date
Application number
MX2021001145A
Other languages
English (en)
Inventor
Ranzani Luis Soler
Cervantes Laura Mestre
Ferraz Rosa Torres
Original Assignee
Sant Joan De Deu Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sant Joan De Deu Hospital filed Critical Sant Joan De Deu Hospital
Publication of MX2021001145A publication Critical patent/MX2021001145A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención se refiere a una formulación de liberación inmediata para administración oral, que comprende; a) una combinación de tres principios activos farmacéuticos que son espironolactona; pioglitazona o una sal de la misma; y metformina o una sal de la misma; y b) polietilenglicol sólido que tiene un peso molecular promedio de 3350 a 8000 g/mol; en la que: cada uno de los principios activos farmacéuticos está presente en una cantidad terapéuticamente efectiva; y el polietilenglicol está presente en una cantidad tal que disminuye los perfiles de disolución in vitro de cada uno de los principios activos farmacéuticos sin modificar el tiempo de disgregación de la formulación en comparación con los perfiles de disolución de cada uno de los principios activos farmacéuticos de una formulación que tiene la misma composición pero sin el polietilenglicol sólido, así como, a su procedimiento de preparación.
MX2021001145A 2018-08-02 2019-08-01 Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico. MX2021001145A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382586 2018-08-02
PCT/EP2019/070751 WO2020025742A1 (en) 2018-08-02 2019-08-01 Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome

Publications (1)

Publication Number Publication Date
MX2021001145A true MX2021001145A (es) 2021-06-23

Family

ID=63244530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001145A MX2021001145A (es) 2018-08-02 2019-08-01 Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.

Country Status (7)

Country Link
US (1) US20210290639A1 (es)
EP (1) EP3829546A1 (es)
JP (1) JP2021533109A (es)
KR (1) KR20210045404A (es)
CA (1) CA3107945A1 (es)
MX (1) MX2021001145A (es)
WO (1) WO2020025742A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201518979D0 (en) * 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation
CN114796239A (zh) * 2022-05-13 2022-07-29 上海金不换兰考制药有限公司 一种螺内酯组合物、制剂及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
NZ602809A (en) * 2010-05-05 2015-02-27 Boehringer Ingelheim Int Pharmaceutical formulations comprising pioglitazone and linagliptin
WO2016059219A1 (en) * 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3025707A1 (en) * 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. A multilayer tablet comprising metformin and pioglitazone
GB201518979D0 (en) * 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation

Also Published As

Publication number Publication date
WO2020025742A1 (en) 2020-02-06
EP3829546A1 (en) 2021-06-09
WO2020025742A9 (en) 2020-10-08
US20210290639A1 (en) 2021-09-23
CA3107945A1 (en) 2020-02-06
KR20210045404A (ko) 2021-04-26
JP2021533109A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
WO2015120110A3 (en) Novel pharmaceutical formulations
CY1123006T1 (el) Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης
WO2005086700A3 (en) Hiv integrase inhibitors
NO20081325L (no) Nye doseringsformuleringer
MX2019011491A (es) Formulaciones de niraparib.
WO2004108162A3 (en) Controlled release pharmaceutical composition
AU2001278696A1 (en) Aqueous pharmaceutical compositions
BRPI0518781A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
MX2021001145A (es) Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.
WO2005120516A3 (en) Hiv integrase inhibitors
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
MX2020008360A (es) Forma cristalina de bictegravir sodico.
JP2015504094A5 (es)
MX2022006940A (es) Composiciones farmaceuticas.
WO2004078111A3 (en) Extended release minocycline compositions and processes for their preparation
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
HRP20201436T1 (hr) Makrogoli za davanje na sluznicu i njihove terapeutske primjene
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
WO2016195194A3 (ko) 신규한 tlr2 길항제
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
EA201800091A1 (ru) Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
MX2021015727A (es) Derivados de piridin-3-ilo.
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin